Synopsis
Nature Medicine, Published online: 24 October 2026; doi:10.1038/s41591-026-04740-9 As presented at the ESMO Congress 2026: In this exploratory, nonrandomized phase 2a trial, treatment of patients with immune checkpoint inhibitor-naive muscle-invasive bladder cancer with the GDF-15-neutralizing antibody visugromab and nivolumab produced encouraging pathological complete response and radiographic response rates with no new safety signals, supporting further evaluation in larger randomized studies.
The publisher’s own description. This is a short summary, not the full story, and may omit important detail.
Read the full story at Nature Medicine ↗
